Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 45Neoplasm Metastasis 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Bulbo-Spinal Atrophy, X-Linked 2Bites and Stings 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Pancreatic Neoplasms 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Newly Diagnosed Oligometastatic Prostate Cancer 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1

Interventions

apalutamide 1abiraterone 1Radiosurgery 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic Disease × abiraterone × 1 year × Clear all
NCT06832774 2026-03-25

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
192 enrolled
Genitourinary

Prostate Cancer Metastatic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡